← All trials
NCT05540717
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Nov 30, 2023
- First posted
- Sep 15, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 1204
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allergy TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.